MCM
TNGX icon

MAI Capital Management’s Tango Therapeutics TNGX Stock Holding History

MAI Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18
Closed -$377 – 4498
2026
Q1 		$377 Buy
+18
New +$251 ﹤0.01% 4480

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

MAI Capital Management's TNGX Position: Q2 2026 in Review

MAI Capital Management sold out of Tango Therapeutics (TNGX) in Q2 2026, closing a stake of 18 shares — an estimated $377 sold.

MAI Capital Management first reported a position in TNGX in Q1 2026 and held it in 1 quarter. The position peaked at $377 in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • MAI Capital Management reported no remaining Tango Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 18 Tango Therapeutics shares in Q2 2026, an estimated $377.
  • MAI Capital Management first reported a position in Tango Therapeutics in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Tango Therapeutics position peaked at $377 in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.